

Catalyst Pharmaceutical Partners, Inc.
220 Miracle Mile
Suite 234
Coral Gables, Florida 33134

November 6, 2006

VIA EDGAR

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E., Mail Stop 6010
Washington, DC 20549
Attn: Jeffrey Reidler, Assistant Director

Re: Catalyst Pharmaceutical Partners, Inc.
Registration Statement on Form S-1
Commission File No. 333-136039

Dear Mr. Reidler:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), Catalyst Pharmaceutical Partners, Inc. (the "Company") requests that the effectiveness of the above-referenced Registration Statement be accelerated at 2:00 p.m. on Tuesday, November 7, 2006, or as soon as possible thereafter.

As requested, the Company acknowledges that:

- should the Commission or the staff declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
- the action of the Commission or the staff, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosures in the filing; and
- the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Sincerely,

/s/ Patrick J. McEnany

Patrick J. McEnany
President and Chief Executive Officer
Catalyst Pharmaceutical Partners, Inc.

November 6, 2006

Mr. Jeffrey Reidler
Assistant Director, Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Mail Stop 6010
Washington, D.C. 20549-6010

**Re: Catalyst Pharmaceutical Partners, Inc.
Registration Statement on Form S-1
File No. 333-136039**

Dear Mr. Reidler:

In connection with the proposed offering of common stock of Catalyst Pharmaceutical Partners, Inc. contemplated by the above-captioned Registration Statement, we wish to advise you that we, as representatives of the underwriters, hereby join with Catalyst Pharmaceutical Partners' request that the effective date of the above-captioned Registration Statement be accelerated so that the same will become effective on November 7, 2006 at 2:00 P.M., New York City time or as soon as practicable thereafter.

The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:

- (i) Date of preliminary prospectus: October 4, 2006.
- (ii) Dates of distribution: October 4, 2006 — November 6, 2006
- (iii) Number of prospective underwriters and dealers to whom the preliminary prospectus was furnished: 7
- (iv) Number of preliminary prospectuses furnished to others: none
- (v) Number of prospectuses so distributed: approximately 2,350
- (vi) Steps taken to comply with Rule 15c2-8 under the Securities Exchange Act of 1934: Included in Master Agreement Among Underwriters of First Albany Capital Inc.

Very truly yours,

FIRST ALBANY CAPITAL INC.
STIFEL NICOLAUS & COMPANY, INCORPORATED

By: FIRST ALBANY CAPITAL INC.

By: /s/ J. Scott Coburn

Name: J. Scott Coburn

Title: Managing Director